Rectal Aberrant Crypt Foci in Humans Are Not Surrogate Markers for Colorectal Cancer Risk

dc.contributor.authorQuintanilla Leo, Isabel
dc.contributor.authorLópez-Cerón Pinilla, María
dc.contributor.authorJimeno, Mireya
dc.contributor.authorCuatrecasas Freixas, Miriam
dc.contributor.authorZabalza, Michel
dc.contributor.authorMoreira Ruiz, Leticia
dc.contributor.authorAlonso-Espinaco, Virginia
dc.contributor.authorRodríguez de Miguel, Cristina
dc.contributor.authorMuñoz, Jenifer
dc.contributor.authorCastellví Bel, Sergi
dc.contributor.authorLlach Vila, Josep
dc.contributor.authorCastells Garangou, Antoni
dc.contributor.authorBalaguer Prunés, Francesc
dc.contributor.authorCamps, Jordi
dc.contributor.authorPellisé Urquiza, Maria
dc.date.accessioned2020-06-15T22:05:02Z
dc.date.available2020-06-15T22:05:02Z
dc.date.issued2019-05-15
dc.date.updated2020-06-15T22:05:02Z
dc.description.abstractNTRODUCTION: Over the past 20 years, aberrant crypt foci (ACF) have emerged as potential precursors and biomarkers for colorectal cancer (CRC). However, data regarding their molecular pathogenesis, as well as their endoscopic and histological identification, remain inconsistent. METHODS: A wide cohort of ACF from 100 control subjects and 100 case patients, including patients with adenoma and CRC, were characterized for endoscopic, morphologic, and molecular features. RESULTS: We observed that among all the endoscopic features evaluated, only the number of large ACF correlated with CRC risk (P = 0.003), whereas the histological classification, as assessed by 2 different pathologists, was inconsistent and did not differ between control and case patients. Moreover, only a few APC and BRAF mutations and no microsatellite instability were detected in our samples. KRAS mutations were detected in 16.3% of ACF samples, which also exhibited increased MGMT hypermethylation. However, none of those events were found to be predictive of CRC risk. DISCUSSION: Although ACF might be preneoplastic lesions of the colon, they are not suitable biomarkers for assessing CRC progression.
dc.format.extent8 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec695490
dc.identifier.issn2155-384X
dc.identifier.pmid31136360
dc.identifier.urihttps://hdl.handle.net/2445/165670
dc.language.isoeng
dc.publisherWolters Kluwer Health
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.14309/ctg.0000000000000047
dc.relation.ispartofClinical and Translational Gastroenterology, 2019, vol. 10, num. 6, p. 00047
dc.relation.urihttps://doi.org/10.14309/ctg.0000000000000047
dc.rightscc-by-nc-nd (c) Quintanilla, Isabel et al., 2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es
dc.sourceArticles publicats en revistes (Fonaments Clínics)
dc.subject.classificationCàncer colorectal
dc.subject.classificationEtiologia
dc.subject.classificationEndoscòpia
dc.subject.otherColorectal cancer
dc.subject.otherEtiology
dc.subject.otherEndoscopy
dc.titleRectal Aberrant Crypt Foci in Humans Are Not Surrogate Markers for Colorectal Cancer Risk
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
695490.pdf
Mida:
417.96 KB
Format:
Adobe Portable Document Format